(Acute Inflammatory Demyelinating Polyradiculoneuropathy; Acute Inflammatory Demyelinating Polyneuropathy; Acute Idiopathic Polyneuritis; Acute Inflammatory Polyneuropathy; Acute Autoimmune Neuropathy; Idiopathic Polyneuritis; AIDP)
Pronounced: gee-yan bah-ray sin-droam
by Michelle Badash, MS
Guillain-Barré syndrome is a rare condition that causes the immune system to attack the nerves outside of the brain and spinal cord. It is characterized by numbness, tingling, weakness, or paralysis in the legs, arms, breathing muscles, and face. It can affect all ages.
The exact cause of Guillain-Barré syndrome is unknown. However in about three-fourths of people, a recent infection or surgery triggers an autoimmune response. This autoimmune response attacks the peripheral nerves, leading to weakness and a loss of sensation.
Guillain-Barré syndrome is more common in men, and in the those aged 15-35 years and 60-75 years old. Other factors that increase your chance of Guillain-Barré syndrome may include:
The first symptoms of Guillain-Barré syndrome include:
Symptoms may develop over a period of hours, days, or weeks. They will vary in severity from minimal to total paralysis including respiratory weakness. The symptoms progress and worsen. Most people experience the greatest weakness during the second or third week.
Related complications include:
Most people fully recover, but others may have residual symptoms, or permanent or disabling problems.
You will be asked ask about your symptoms and medical history. A physical exam will be done.
Tests may include:
Treatment aims to reduce the body’s autoimmune response and decrease complications that result from immobility. Hospitalization is important because symptoms may rapidly become more severe, including respiratory failure, heart arrhythmias, and blood pressure instability.
Common treatments include:
During plasmapheresis, blood is removed from your body and passed through a machine that separates blood cells. The separated cells are then returned to your body with new plasma. This procedure may help shorten the course and severity of Guillain-Barré syndrome.
High-dose Immunoglobulin Therapy
IV infusion with immunoglobulin (IVIg) may help reduce the severity of a Guillain-Barré attack. Immunoglobulins are proteins that are naturally produced by the body’s immune system.
In some cases, muscles necessary for breathing become paralyzed. This is treated with immediate emergency support from a mechanical ventilator.
Your doctor may advise
There are no current guidelines to prevent Guillain-Barré syndrome.
Guillain-Barré Syndrome Foundation International
National Institute of Neurological Disorders and Stroke
Canadian Institute for Health Information
Guillain-Barre syndrome. EBSCO DynaMed Plus website. Available at: Available at: http://www.dynamed... . Updated April 28, 2017. Accessed February 14, 2018.
Vucic S, Kiernan MC, Cornblath DR. Guillain-Barre: an update. J Clinical Neuroscience. 2009;16(6):733-741.
Last reviewed March 2018 by EBSCO Medical Review Board Rimas Lukas, MD
Last Updated: 5/7/2014
EBSCO Information Services is fully accredited by URAC. URAC is an independent, nonprofit health care accrediting organization dedicated to promoting health care quality through accreditation, certification and commendation.
This content is reviewed regularly and is updated when new and relevant evidence is made available. This information is neither intended nor implied to be a substitute for professional medical advice. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with questions regarding a medical condition.
To send comments or feedback to our Editorial Team regarding the content please email us at firstname.lastname@example.org. Our Health Library Support team will respond to your email request within 2 business days.